Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

ion with methotrexate. In preclinical studies, Rigel's R788 was shown to diminish the swelling and tissue destruction associated with RA. In addition, in a murine model of ITP, R788 was shown to increase platelet counts significantly.

Lymphoma is a large class of blood cancers that affect the lymphoid system, which is part of the immune system. In 2006, lymphoma affected an estimated 500,000 people in the United States, with 332,000 of them suffering from non-Hodgkin's varieties of the disease. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma and is generally categorized as aggressive, marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow and other organs.

A variety of treatment options exist, including chemotherapy and radiation, but the five-year survival rate for non-Hodgkin's lymphoma patients is estimated to be around 50%. Even for those who respond to treatment, recurrence of the disease is common.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates, the timing of results thereof and the potentia
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:7/29/2015)... YORK, Pa. , July 29, 2015  Unilife ... and ASX: UNS), a developer, manufacturer and supplier of ... a multifaceted financing strategy that provides the Company with ... Unilife has signed an equity purchase ... Capital Fund, LLC ("LPC"), a Chicago ...
(Date:7/29/2015)... July 29, 2015  Nektar Therapeutics (Nasdaq: NKTR ) ... June 30, 2015 on Wednesday, August 5, 2015, after the ... and chief executive officer, will host a conference call to ... p.m. Pacific Time (PT). The press release ... be accessed through a link that is posted on the ...
(Date:7/29/2015)... and BERKELEY, Calif. , ... Plexxikon Inc., a member of the Daiichi Sankyo Group, ... Medicine (NEJM) published clinical trial results demonstrating that ... induced prolonged tumor regressions in most patients with tenosynovial ... of the joint or tendon sheath. Following ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
... SAN FRANCISCO, Oct. 17 Proteolix, Inc. today announced ... will be presented at the 2009 ACR/ARHP Annual Scientific ... Carfilzomib is the first in a new class ... patients in multiple oncology clinical trials, including a Phase ...
... Oct. 16 Pfizer Inc., through a wholly owned subsidiary, ... federal district court in Boston as part of a plea ... the illegal marketing of the painkiller Bextra for unsafe and ... pharmaceutical company had for patients, lives by putting profits above ...
Cached Medicine Technology:Proteolix to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting 2Proteolix to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting 3Whistleblower's Attorney Says Pfizer's Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... New Tool That Increases Training Capability , World renown body weight ... Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , The ...
(Date:7/30/2015)... ... July 30, 2015 , ... Using the latest online ... teach people more effective ways to prevent and manage major depression. , “Suicide is ... enough, so people fall through the cracks and die needlessly everyday,” says Walker. “I’m ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of Florida ... system, which has amassed largely enough throughout the years. Florida is the third state ... recent reduction of non violent drug offender’s prison sentences, Florida is beginning to take ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
(Date:7/30/2015)... Newark, NJ (PRWEB) , ... July 30, 2015 ... ... New Jersey's State-designated entity on behalf of the New Jersey Department of Health, ... for Health Information Technology, an agency of the U.S. Department of Health and ...
Breaking Medicine News(10 mins):Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- An ... to have passed an initial hurdle by proving safe ... designed to look at safety, researchers scheduled to present ... meeting in Chicago also report that anacetrapib raised HDL ...
... News) -- The U.S. Food and Drug Administration on Wednesday ... illegal. In warning letters to the companies, the agency ... "unsafe food additive," and the companies risked further action, including ... for the claim that the addition of caffeine to these ...
... named Walter and Eliza Hall Institute researcher Dr Benjamin Kile ... Minister,s Prize for Life Scientist of the Year is awarded ... the potential to advance, human welfare. Dr Kile, ... be presented with the award tonight by the Hon. Kim ...
... Institute of Public Health (NIPH) shows that children with severe ... 18 months of age compared to healthy children. Children with ... not show an increased risk of anxiety. - ... heart defects are prone to emotional problems at a very ...
... not have a chance to fight health problems if ... Non-adherence to medications costs thousands of lives and billions ... according to the New England Healthcare Institute. Now, researchers ... strategy that is three times more effective than previously ...
... that patients suffering back pain get quicker diagnosis and ... Traditionally, patients face long and anxiety-ridden wait times - ... by a spine surgeon. Results from the year long ... a Nurse Practitioner were significantly shorter, ranging from 10 ...
Cached Medicine News:Health News:Experimental Drug Raises Good Cholesterol Levels in Early Trial 2Health News:Experimental Drug Raises Good Cholesterol Levels in Early Trial 3Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:Dr. Benjamin Kile named 2010 Australian Life Scientist of the Year 2Health News:Doubled risk of anxiety for 18 month-old children with congenital heart defects 2Health News:Researchers fight America's 'other drug problem' 2Health News:Toronto Western Hospital study demonstrates improved wait times for patients suffering back pain 2
... cutting speeds (guillotine movements) are possible. Cutting ... off, thus minimizing tissue trauma. One can ... both can be combined together. There are ... bi-manual techniques. Lightweight autoclavable hand-pieces with single ...
A wide selection of bipolar forceps and hemostatic erasers to facilitate most ophthalmic surgical procedures....
Enables Delicate Lifting Of The Flap Without Causing Trauma - Also available in Titanium...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
Medicine Products: